Thermo Fisher Scientific Obinutuzumab Monoclonal Antibody (16B7)
인간 CD20을 표적으로 하는 마우스 단클론 항체로, Obinutuzumab 연구용으로 사용됩니다. ELISA에 적합하며, 동결건조 형태로 제공됩니다. Protein A로 정제되었으며, PBS 버퍼(pH 7.4, 1% BSA)와 0.02% sodium azide를 포함합니다.
- 카탈로그번호
- A0194740
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Obinutuzumab Monoclonal Antibody (16B7)
Applications
ELISA (ELISA)
- Tested Dilution: 0.01–1 µg/mL
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Mouse / IgG2a, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Clone | 16B7 |
| Immunogen | Obinutuzumab |
| Conjugate | Unconjugated |
| Form | Lyophilized |
| Purification | Protein A |
| Storage buffer | PBS, pH 7.4, with 1% BSA |
| Contains | 0.02% sodium azide |
| Storage conditions | -20°C or -80°C if preferred |
| Shipping conditions | Ambient (domestic); Wet ice (international) |
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second-line treatment for follicular lymphoma.
Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. It binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Target Information
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second-line treatment for follicular lymphoma.
Obinutuzumab binds to CD20 on B cells, triggering cell destruction through immune engagement, apoptosis activation, and complement system activation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기
문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.